Concepedia

Publication | Open Access

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

DOIFull Paper Access

124

Citations

19

References

2009

Year

Amyé Tevaarwerk, Kyle D. Holen, Dona Alberti, Carolyn Sidor, Jamie Arnott, Check Y. Quon, George Wilding, Glenn Liu
Clinical Cancer Research

Abstract

For 2ME2 NCD, the MTD and recommended phase II regimen is 1,000 mg orally every 6 hours. Treatment was generally well-tolerated.

References

YearCitations

Page 1